
MedCram
Episode 81. Current COVID Risk Assessment: BA.2.86 Variant, Boosters, and More
Sep 12, 2023
Dr. Roger Seheult examines the COVID risk assessment, including the BA.2.86 Variant, boosters, hospitalizations, and T cell immunity. He also discusses a study on myocarditis in COVID-19 recovered patients and factors to consider for booster shots.
24:30
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The BA 2.86 variant of SARS-CoV-2 may not be as significant a threat as initially thought, as other variants are responsible for the majority of infections and hospitalizations.
- Updated booster shots, like the Moderna booster, can significantly increase neutralizing antibody levels against circulating variants, but risks such as myocarditis should be discussed with healthcare providers.
Deep dives
Prevalence of the virus and hospitalizations
The prevalence of COVID-19 is increasing nationwide based on wastewater detection, indicating a steady rise in the disease. Hospitalizations have also increased proportionally in both the United States and Canada, suggesting that the benefits of vaccination and previous infection may be wearing off.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.